IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
2020
AbstractBuparlisib is an orally available pan-Class I PI3K inhibitor, that is more potent than idelalisib in vitro. Its distinct toxicities include hyperglycemia, hypertension, and mood disturbance...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
1
Citations
NaN
KQI